Table 2 Histological features and outcomes of pancreatic solitary fibrous tumors
From: Malignant solitary fibrous tumor of the pancreas: a case report
Author | Positive immunohistochemistry | Malignant features | Diagnosis of malignant SFT | Recurrence | Outcome | Follow-up |
|---|---|---|---|---|---|---|
Lüttges et al. [5] | CD34, CD99, Bcl-2, vimentin | No | No | No | Alive | 20 mo |
Chatti et al. [7] | CD34, CD99, Bcl-2, vimentin | No | No | No | Died postoperative complications | 3 d |
Gardini et al. [8] | CD34, CD99, Bcl-2, vimentin, SMA (focal) | NA | No | No | Alive | 16 mo |
Miyamoto et al. [9] | CD34, Bcl-2 | No | No | No | Alive | 7 mo |
Srinivasan et al. [10] | CD34, Bcl-2 | No | No | No | Alive | 7 mo |
Kwon et al. [11] | CD34, CD99, vimentin | No | No | No | NA | NA |
Ishiwatari et al. [12] | CD34, Bcl-2 | Necrosis | No | No | Alive | 42 mo |
Chetty et al. [13] | CD34, CD99, Bcl-2 | No | No | No | Alive | 6 mo |
Sugawara et al. [14] | CD34 | No | No | No | NA | NA |
Santos et al. [15] | CD34, beta-catenin | No | No | No | NA | NA |
Tasdemir et al. [16] | CD34, Bcl-2, beta-catenin, vimentin, Ki67 < 2% | No | No | No | Alive | 3 mo |
Azadi et al. [17] | CD34, Bcl-2, Ki67 < 5% | No | No | No | NA | NA |
van der Vorst et al. [18] | CD34, CD99, Bcl-2 | No | No | No | NA | NA |
Yamanashi et al. [19] | CD34, vimentin, Bcl-2 | Intra-pancreatic metastasis, necrosis, > 2 mitoses/HPFs, hypercellularity | Yes | Intra-pancreatic | Alive | 32 mo |
Chen et al. [20] | CD34, Bcl-2, vimentin, CD68, muscle-specific actin | Necrosis | No | No | Alive | 30 mo |
Hwang et al. [21] | CD34, Bcl-2, muscle-specific actin, CD10, ER, PR | No | No | No | Alive | 30 mo |
Han et al. [22] | CD34, CD99 | No | No | – | No progression | 10 mo |
Estrella et al. [23] | CD34, Bcl-2, keratin (rare), p16, p53 | Nuclear atypia, necrosis 17 mitoses/10 HPFs, | Yes | No | Alive | 40 mo |
Baxter et al. [24] | CD34, Bcl-2 | NA | No | No | NA | NA |
Paramythiotis et al. [25] | CD34, CD99, Bcl-2, vimentin, S-100 (focal) | No | No | No | Alive | 40 mo |
Murakami et al. [26] | STAT6, CD34, Bcl-2, ACTH (focal), POMC (focal), NSE (focal) | No | No | No | Died sepsis | 4 mo |
Spasevska et al. [27] | CD34, vimentin, CD99, Bcl-2 (focal), nuclear beta-catenin (focal) | No | No | No | Died postoperative complications | 1 wk |
Clare et al. [28] | STAT6, CD34, Bcl-2, CD56, cytokeratin CAM5.2, AE1/AE3 | 6/10 HPFs | Yes | No | Alive | 40 mo |
Sheng et al. [29] | CD34, vimentin, SMA (focal), Ki67 < 3% | Mild–moderate nuclear pleomorphism 2–5/10 HPFs hypercellularity | No | No | Alive | 12 mo |
D'Amico et al. [30] | STAT6, CD34 | No | No | No | Alive | 24 mo |
Oana et al. [31] | CD34, Bcl-2 | No | No | No | Alive | 36 mo |
Geng et al. [32] | STAT6, CD34, Bcl-2, CD31, PHH-3, D2-40, Ki67 > 10% | 4–5/10 HPFs necrosis | Yes | Residual liver tumor ( +) | Alive | 6 mo |
Qian et al. [33] | STAT6, CD34, Bcl-2, Ki67 10% | Heterotypic cell 4–5/10 HPFs local infarction | Yes | NA multiple recurrence | Alive | 10 mo |
Present case | STAT6, CD34, Bcl-2, vimentin, cytokeratin AE1/AE3(focal) | Hypercellularity 12/10 HPFs necrosis invasive growth | Yes | No | Alive | 12 mo |